nChroma Bio stops its only clinical study early, lays off 50%
A couple of years ago, two Boston-area biotech CEOs decided to merge their startups, hoping to survive a down market for genetic medicine companies. Jeff Walsh, the CEO of that combined company, nChroma Bio,
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.